BACKGROUND: Mesenchymal stem cells are multipotent and have the ability to differentiate into bone. We conducted a preclinical trial comparing the osteogenic potential of human bone marrow aspirate with that of mesenchymal stem cell-enriched bone marrow aspirate (both mixed with demineralized bone matrix) in a critical-sized rat femoral defect model. METHODS: The buffy coat was extracted from human bone marrow aspirate to obtain mesenchymal stem cell-enriched bone marrow aspirate. Fifty-nine athymic rats, each with a 6-mm femoral defect, were divided into six treatment groups: defect only (Group I), demineralized bone matrix and saline solution (Group II), demineralized bone matrix and bone marrow aspirate (Group III), demineralized bone matrix and mesenchymal stem cell-enriched bone marrow aspirate (Group IV), demineralized bone matrix and recombinant human bone morphogenetic protein-2 (rhBMP-2) (Group V [positive control]), and absorbable collagen sponge and rhBMP-2 (Group VI [positive control]). All animals were killed at twelve weeks for radiographic, micro-computed tomography, histomorphometric, and histologic analysis. RESULTS: There was wide variability in the mesenchymal stem cell concentrations obtained from the human donors. All ten defects healed in the positive control groups (Groups V and VI). Only one defect healed in each experimental group (Groups II, III, and IV) (i.e., three of forty-four defects healed). There was no significant difference among the radiographic scores of Groups II, III, and IV (p = 0.59), and the score for each of those groups was significantly higher than that for Group I (p <or= 0.005) and significantly lower than those for Groups V and VI (p <or= 0.001). The bone volume and mineral density did not differ among Groups III, IV, and V (p = 0.53). The percent total bone volume and percent normal bone volume in Group VI were significantly higher than those values in Groups I, III, and IV (p < 0.0001) and those in Group II (p = 0.048). In Groups II through V, the cortical bone was more dense than the lace-like bone in Group VI. CONCLUSIONS: Neither bone marrow aspirate nor mesenchymal stem cell-enriched bone marrow aspirate mixed with demineralized bone matrix resulted in reliable healing of critical-sized bone defects. It is possible that a greater number of mesenchymal stem cells or an enhanced osteoinductive signal is required for adequate bone-healing. Mesenchymal stem cell and/or carrier variability may also contribute to differences in bone formation.
BACKGROUND: Mesenchymal stem cells are multipotent and have the ability to differentiate into bone. We conducted a preclinical trial comparing the osteogenic potential of human bone marrow aspirate with that of mesenchymal stem cell-enriched bone marrow aspirate (both mixed with demineralized bone matrix) in a critical-sized rat femoral defect model. METHODS: The buffy coat was extracted from human bone marrow aspirate to obtain mesenchymal stem cell-enriched bone marrow aspirate. Fifty-nine athymic rats, each with a 6-mm femoral defect, were divided into six treatment groups: defect only (Group I), demineralized bone matrix and saline solution (Group II), demineralized bone matrix and bone marrow aspirate (Group III), demineralized bone matrix and mesenchymal stem cell-enriched bone marrow aspirate (Group IV), demineralized bone matrix and recombinant humanbone morphogenetic protein-2 (rhBMP-2) (Group V [positive control]), and absorbable collagen sponge and rhBMP-2 (Group VI [positive control]). All animals were killed at twelve weeks for radiographic, micro-computed tomography, histomorphometric, and histologic analysis. RESULTS: There was wide variability in the mesenchymal stem cell concentrations obtained from the human donors. All ten defects healed in the positive control groups (Groups V and VI). Only one defect healed in each experimental group (Groups II, III, and IV) (i.e., three of forty-four defects healed). There was no significant difference among the radiographic scores of Groups II, III, and IV (p = 0.59), and the score for each of those groups was significantly higher than that for Group I (p <or= 0.005) and significantly lower than those for Groups V and VI (p <or= 0.001). The bone volume and mineral density did not differ among Groups III, IV, and V (p = 0.53). The percent total bone volume and percent normal bone volume in Group VI were significantly higher than those values in Groups I, III, and IV (p < 0.0001) and those in Group II (p = 0.048). In Groups II through V, the cortical bone was more dense than the lace-like bone in Group VI. CONCLUSIONS: Neither bone marrow aspirate nor mesenchymal stem cell-enriched bone marrow aspirate mixed with demineralized bone matrix resulted in reliable healing of critical-sized bone defects. It is possible that a greater number of mesenchymal stem cells or an enhanced osteoinductive signal is required for adequate bone-healing. Mesenchymal stem cell and/or carrier variability may also contribute to differences in bone formation.
Authors: Elena Veronesi; Alba Murgia; Anna Caselli; Giulia Grisendi; Maria Serena Piccinno; Valeria Rasini; Rosaria Giordano; Tiziana Montemurro; Philippe Bourin; Luc Sensebé; Markus T Rojewski; Hubert Schrezenmeier; Pierre Layrolle; Maria Pau Ginebra; Carmen Bunu Panaitescu; Enrique Gómez-Barrena; Fabio Catani; Paolo Paolucci; Jorge S Burns; Massimo Dominici Journal: Tissue Eng Part C Methods Date: 2013-08-20 Impact factor: 3.056
Authors: Liisa T Kuhn; Yongxing Liu; Nolan L Boyd; James E Dennis; Xi Jiang; Xiaonan Xin; Lyndon F Charles; Liping Wang; H Leonardo Aguila; David W Rowe; Alexander C Lichtler; A Jon Goldberg Journal: Tissue Eng Part A Date: 2013-10-04 Impact factor: 3.845
Authors: Hangama C Fayaz; Peter V Giannoudis; Mark S Vrahas; Raymond Malcolm Smith; Christopher Moran; Hans Christoph Pape; Christian Krettek; Jesse B Jupiter Journal: Int Orthop Date: 2011-08-24 Impact factor: 3.075
Authors: Mandeep S Virk; Osamu Sugiyama; Sang H Park; Sanjiv S Gambhir; Douglas J Adams; Hicham Drissi; Jay R Lieberman Journal: Mol Ther Date: 2011-02-22 Impact factor: 11.454
Authors: Sofia Bougioukli; Osamu Sugiyama; William Pannell; Brandon Ortega; Matthew H Tan; Amy H Tang; Robert Yoho; Daniel A Oakes; Jay R Lieberman Journal: Hum Gene Ther Date: 2018-03-14 Impact factor: 5.695
Authors: Mandeep S Virk; Farhang Alaee; Hezhen Tang; Michael S Ominsky; Hua Zhu Ke; Jay R Lieberman Journal: J Bone Joint Surg Am Date: 2013-04-17 Impact factor: 5.284